Cancer Immunotherapy Market Research Report- Forecast till 2023

Report / Search Code: MRFR/HC/0124-HCRR  
Publish Date: 23 June, 2018

Description:

Global Cancer Immunotherapy Market Research Report: By Type of Therapy (Monoclonal Antibodies, Adoptive Cell Transfer and others), By Application (Lung Cancer, Childhood Cancer and other), By End User (Hospitals, Clinics & others) - Forecast till 2023

Market Scenario

Global cancer immunotherapy market has been growing at a impressive rate in recent years and will maintain the same in coming future. Approximately 100 different types of cancer have been identified. Cancer is condition of uncontrolled cell growth. Cancer Immunotherapy, on the other hand, helps the immune system to target cancerous tumor cells, which is in fact the natural tendency of the body but tends to weaken with the advent of disease infections. According to W.H.O. cancer is the leading cause of the total number of deaths globally in 2015, and was responsible for 8.8 million deaths in 2015. Statistics suggest that nearly 1 in 6 patients die due to cancer. Due to deteriorating lifestyle, smoking, and alcoholism are responsible for increasing the incidence of cancer. Increasing cancer population is the major reason for increasing the global immunotherapy market. Many therapies are available in the market but the advantage of immunotherapy is its high effectiveness and less side effects as compared to other therapies. This therapy is effective for patients suffering from melanoma cancer when chemotherapy and other radiation therapies do not work.

The respective statistics of deaths occurring due to lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer were recorded to be found as 16,90,000, 788,000, 774,000, 754,000, and 571,000 respectively, in 2015.

Most common cancers are lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer, which have been recorded to cause 1.69 million, 788,000, 774 thousands, 754 thousands, and 571 thousands deaths respectively in year 2015.

According to CDC, more than 1.5 million people are diagnosed with cancer.
every year in the U.S., and more than 5 lakhs people are not able to survive. Reports show that 50% of the total deaths could be prevented through making a healthy choice. Smoking is the leading cause of lung cancer, which is responsible for 90% of the total deaths in men and 80% in women.

Global immunotherapy market was USD 36.8 billion in 2016 which is expected to grow at a healthy CAGR of 14.8% and reach till USD 101.6 billion by 2023.

Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation

Intended Audience

- Government and private research companies
- Research and Development (R&D) Companies
- Drug Manufacturers and Suppliers
- Hospitals and Laboratories
- Medical Research Laboratories

Segmentations

The global cancer immunotherapy market is segmented on the basis of therapy types, by application, by end user.
On the basis of type, it is segmented into monoclonal antibodies, adoptive cell transfer, cytokines, treatment vaccines, bacillus calmette-guérin, and others. Monoclonal antibodies segment is further segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, and bispecific monoclonal antibodies. Cytokines are further segmented into Interferon, Interleukins.

On the basis of application, it is segmented into liver cancer, childhood cancer, colorectal cancer, stomach cancer, lung cancer and others.

On the basis of end user, it is segmented into hospitals, clinics, and others.

**Figure: Global Cancer Immunotherapy Market, by type of therapy Market Share, 2016 (%)**

Sources: Annual reports, Press release, White paper, Company presentation

**Regional Analysis**

Global cancer immunotherapy market is segmented into four main geographical region, they are North America, Europe, Asia Pacific and The Middle East and Africa.

Over the last few years, North America and Europe are the major contributors in the global cancer immunotherapy market. Due to their reputation as a suitable place for research and development. The market for cancer immunotherapy has a huge demand in both region and is expected to grow in coming future.

Asia Pacific is however the fastest growing cancer immunotherapy market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover increasing demand for new treatment methods in countries like India and South Korea are likely to emerge as the fastest growing market across the globe.

The Middle East and Africa holding the least growth in comparison to other region, although, increasing occurrence of cancer owing to smoking, change in lifestyle, and excessive alcohol intake are driving the cancer immunotherapy market in this region.
**Key Players**

Some of key the players in the market are F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis International AG, GlaxoSmithKline Plc., Amgen Inc., Bristol-Myers Squibb, ELI Lilly and Company, Celgene Corporation, Seattle Genetics, Inc., Spectrum Pharmaceuticals, Inc.

---

**Contents:**

1. Report Prologue
2. Market Introduction
   2.1 Definition
   2.2 Scope of the Study
      2.2.1 Research Objective
      2.2.2 Assumptions
      2.2.3 Limitations
3. Research Methodology
   3.1 Introduction
   3.2 Primary Research
   3.3 Secondary research
   3.4 Market Size Estimation
4. Market Dynamics
   4.1 Drivers
   4.2 Restraints
   4.3 Opportunities
   4.4 Challenges
   4.5 Macroeconomic Indicators
   4.6 Technology Trends & Assessment
5. Market Factor Analysis
   5.1 Porters Five Forces Analysis
      5.1.1 Bargaining Power of Suppliers
      5.1.2 Bargaining Power of Buyers
      5.1.3 Threat of New Entrants
      5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Cancer Immunotherapy Market, By Therapy Type

6.1 Introduction

6.2 Monoclonal Antibodies

6.2.1 Market Estimates & Forecast, 2017-2023

6.3 Adoptive cell transfer

6.3.1 Market Estimates & Forecast, 2017-2023

6.4 Cytokines

6.4.1 Interferon (INFs)

6.4.2 Interleukins (ILs)

6.4.3 Market Estimates & Forecast, 2017-2023

6.5 Treatment Vaccines

6.5.1 Market Estimates & Forecast, 2017-2023

6.6 Bacillus Calmette-Guérin

6.6.1 Market Estimates & Forecast, 2017-2023

6.7 Others

7. Global Cancer Immunotherapy Market, By Application

7.1 Introduction

7.2 Liver cancer

7.2.1 Market Estimates & Forecast, 2017-2023

7.3 Childhood cancer

7.3.1 Market Estimates & Forecast, 2017-2023

7.4 Colorectal cancer

7.4.1 Market Estimates & Forecast, 2017-2023

7.5 Stomach cancer

7.5.1 Market Estimates & Forecast, 2017-2023

7.6 Lung cancer

7.6.1 Market Estimates & Forecast, 2017-2023

7.7 Others
8. Global Cancer Immunotherapy Market, by End User

8.1 Introduction

8.2 Hospitals
8.2.1 Market Estimates & Forecast, 2017-2023

8.3 Clinics
8.3.1 Market Estimates & Forecast, 2017-2023

8.4 Others

9. Global Cancer Immunotherapy Market, by Region

9.1 Introduction

9.2 Americas
9.2.1 North America
9.2.1.1 U.S.
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 U.K
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 F. Hoffmann-La Roche AG

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Merck & Co., Inc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Novartis International AG

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 GlaxoSmithKline Plc

11.4.1 Company Overview
11.9.5 SWOT Analysis

11.10 Spectrum Pharmaceuticals, Inc.

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.10 Others

12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical Industry

13 Appendix

LIST OF TABLES

Table 1 Cancer Immunotherapy Industry Synopsis, 2017-2023

Table 2 Global Cancer Immunotherapy Market Estimates and Forecast, 2017-2023, (USD Million)

Table 3 Global Cancer Immunotherapy Market by Region, 2017-2023, (USD Million)

Table 4 Global Cancer Immunotherapy Market by Therapy Therapy Types, 2017-2023, (USD Million)

Table 5 Global Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)

Table 6 Global Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)

Table 7 North America Cancer Immunotherapy Market by Therapy Therapy Types, 2017-2023, (USD Million)

Table 8 North America Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)

Table 9 North America Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)

Table 10 U.S. Cancer Immunotherapy Market by Therapy Therapy Types, 2017-2023, (USD Million)

Table 10 U.S. Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)
Table 12 U.S. Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)

Table 13 Canada Cancer Immunotherapy Market by Therapy Types, 2017-2023, (USD Million)

Table 14 Canada Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)

Table 15 Canada Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)

Table 16 South America Cancer Immunotherapy Market by Therapy Types, 2017-2023, (USD Million)

Table 17 South America Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)

Table 18 South America Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)

Table 19 Europe Cancer Immunotherapy Market by Therapy Types, 2017-2023, (USD Million)

Table 20 Europe Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)

Table 21 Europe Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)

Table 22 Western Europe Cancer Immunotherapy Market by Therapy Types, 2017-2023, (USD Million)

Table 23 Western Europe Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)

Table 24 Western Europe Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)

Table 25 Eastern Europe Cancer Immunotherapy Market by Therapy Types, 2017-2023, (USD Million)

Table 26 Eastern Europe Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)

Table 27 Eastern Europe Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)

Table 28 Asia Pacific Cancer Immunotherapy Market by Therapy Types, 2017-2023, (USD Million)

Table 29 Asia Pacific Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)

Table 30 Asia Pacific Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)

Table 31 Middle East & Africa Cancer Immunotherapy Market by Therapy Types, 2017-2023, (USD Million)

Table 32 Middle East & Africa Cancer Immunotherapy Market by Application, 2017-2023, (USD Million)

Table 33 Middle East & Africa Cancer Immunotherapy Market by End Users, 2017-2023, (USD Million)
LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Global Cancer Immunotherapy Market
Figure 3 Segmentation Market Dynamics for Cancer Immunotherapy Market
Figure 4 Global Cancer Immunotherapy Market Share, by Type 2016
Figure 5 Global Cancer Immunotherapy Market Share, by Application 2016
Figure 6 Global Cancer Immunotherapy Market Share, by End Users, 2016
Figure 7 Global Cancer Immunotherapy Market Share, by Region, 2016
Figure 8 North America Cancer Immunotherapy Market Share, by Country, 2016
Figure 9 Europe Cancer Immunotherapy Market Share, by Country, 2016
Figure 10 Asia Pacific Cancer Immunotherapy Market Share, by Country, 2016
Figure 10 Middle East & Africa Cancer Immunotherapy Market Share, by Country, 2016
Figure 12 Global Cancer Immunotherapy Market: Company Share Analysis, 2016 (%)
Figure 13 F. Hoffmann-La Roche AG: Key Financials
Figure 14 F. Hoffmann-La Roche AG: Segmental Revenue
Figure 16 F. Hoffmann-La Roche AG: Geographical Revenue
Figure 17 Merck & Co., Inc.: Key Financials
Figure 18 Merck & Co., Inc.: Segmental Revenue
Figure 19 Merck & Co., Inc.: Geographical Revenue
Figure 20 Novartis International AG: Key Financials
Figure 21 Novartis International AG: Segmental Revenue
Figure 22 Novartis International AG: Geographical Revenue
Figure 23 GlaxoSmithKline Plc: Key Financials
Figure 24 GlaxoSmithKline Plc: Segmental Revenue
Figure 25 GlaxoSmithKline Plc: Geographical Revenue
Figure 26 Amgen Inc.: Key Financials
Figure 27 Amgen Inc.: Segmental Revenue
Figure 28 Amgen Inc.: Geographical Revenue
Figure 29 Bristol-Myers Squibb: Key Financials
Figure 30 Bristol-Myers Squibb: Segmental Revenue
Figure 31 Bristol-Myers Squibb: Geographical Revenue